课题基金 / 基金详情

Using Markers to Improve Pancreatic Cancer Screening

Using Markers to Improve Pancreatic Cancer Screening
使用标记物改善胰腺癌筛查
批准号:
10456250
负责人:
Michael G. Goggins
金额:
$40.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
未结题
起止时间:
2013-07-01 至 2025-06-30

项目摘要

项目成果

Michael G. Goggins的其他基金

相似基金

相关文献

中文摘要
翻译
大多数胰腺癌患者表现为晚期不治之症,但患者 诊断为I期胰腺癌的患者预后更好。的早期检测 胰腺癌需要简单有效的胰腺筛查试验, 高危人群。胰腺癌筛查(CAPS)研究目前如下 约1000名患者的家族性/遗传性“高风险”队列接受定期胰腺监测。 CAPS项目的最新结果表明,在胰腺癌的诊断中, 胰腺监测是降级; 40%的人谁保持年度监测, 胰腺癌I期这些结果表明,早期检测可以改善整体 胰腺癌患者的预后。循环肿瘤标志物检测目前还没有 用于胰腺监测。已知遗传因素会影响肿瘤标志物水平,但 基因检测尚未被评估以确定它们是否可以提高肿瘤诊断的准确性。 标记。PI实验室最近的研究表明, 通常使用的肿瘤标志物(CA 19 -9、CA-125和CEA)通过个体的 肿瘤标志物基因型肿瘤标志物基因型检测可以提高诊断的敏感性。 与常规诊断临界值相比,肿瘤标志物的特异性为99%。我们建议 建立肿瘤标志物水平的遗传学定义的正常参考范围, 对接受胰腺成像的患者进行的前瞻性临床试验中的诊断准确性 通过我们的CAPS计划进行监控。每年增加血液检查, 监测有望改善早期胰腺癌的检测。
英文摘要
Most patients with pancreatic cancer present with advanced incurable disease, but patients diagnosed with Stage I pancreatic cancer have a much better outcome. The early detection of pancreatic cancer requires simple and effective pancreatic screening tests that can be applied to high risk populations. The Cancer of the Pancreas Screening (CAPS) study currently follows a familial/genetic “high-risk” cohort of ~1000 patients undergo regular pancreatic surveillance. Recent results from the CAPS program indicate that pancreatic cancers detected during pancreatic surveillance are down-staged; 40% of those who maintained annual surveillance had a Stage I pancreatic cancer. These results indicate that early detection can improve overall outcome of patients with pancreatic cancer. Circulating tumor marker tests are not currently used for pancreas surveillance. Genetic factors are known to influence tumor marker levels, but gene tests have not been evaluated to determine if they could improve the accuracy of tumor markers. Recent studies from the PI's lab indicate that the normal reference ranges of commonly used tumor markers (CA19-9, CA-125 and CEA) are better defined by an individual's tumor marker genotype. A tumor marker genotype test can improve the diagnostic sensitivity of tumor markers at 99% specificity compared to conventional diagnostic cut-offs. We propose to establish genetically-defined normal reference ranges for tumor marker levels and evaluate their diagnostic accuracy in a prospective clinical trial of patients undergoing pancreatic imaging surveillance through our CAPS program. The addition of annual blood tests to pancreatic surveillance is expected to improve the detection of early-stage pancreatic cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using markers to improve pancreatic cancer screening and surveillance
  • 批准号:
    10427584
  • 项目类别:
  • 资助金额:
    $93.17万
  • 财政年份:
    2016
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study
  • 批准号:
    10701743
  • 项目类别:
  • 资助金额:
    $54.46万
  • 财政年份:
    2016
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study
  • 批准号:
    10526649
  • 项目类别:
  • 资助金额:
    $78.66万
  • 财政年份:
    2016
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using Markers to Improve Pancreatic Cancer Screening
  • 批准号:
    8589991
  • 项目类别:
  • 资助金额:
    $41.67万
  • 财政年份:
    2013
  • 负责人:
    Michael G. Goggins
  • 依托单位:
海外基金